Bausch + Lomb (BLCO) reported $1.41 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 9.8%. EPS of $0.32 for the same period compares to $0.25 a year ago.
The reported revenue represents a surprise of +1.58% over the Zacks Consensus Estimate of $1.38 billion. With the consensus EPS estimate being $0.35, the EPS surprise was -7.43%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Bausch + Lomb performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Vision Care: $778 million versus the two-analyst average estimate of $780.35 million. The reported number represents a year-over-year change of +7.6%.
- Revenues- Pharmaceuticals: $378 million versus $355.4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +16% change.
- Revenues- Product sales: $1.4 billion versus $1.37 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.7% change.
- Revenues- Other revenues: $7 million versus the two-analyst average estimate of $5 million. The reported number represents a year-over-year change of +40%.
- Revenues- Surgical: $249 million versus $248.04 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.8% change.
View all Key Company Metrics for Bausch + Lomb here>>>
Shares of Bausch + Lomb have returned +3.7% over the past month versus the Zacks S&P 500 composite's -1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bausch + Lomb Corporation (BLCO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
